2019: Eon Year In Review

Photo of Eon Team Celebrating New Year

Happy New Year from the Eon Team!

Before we jump into 2020 and the exciting new challenges that await, let’s take a quick look back at what was accomplished together (with you!) in 2019.

 

2019 was a busy year for the Eon team! The last twelve months had us traversing the country, performing implementations, ensuring CMS compliance, eliminating clinical workflow inefficiencies, and helping our partners manage their patients using evidence-based guidelines. Eon also earned the opportunity to spend an hour with Eon investor and entrepreneur Mark Cuban to discuss the future of healthcare technology (watch the recorded session here!)

2019: Inside The Numbers

130

Total Live facilities

175

Total Contracted facilities

45

Total Compliance Audits

68,000+

Patients have been touched by our Eon EPM platform!

The Eon team grew stronger in 2019 with the addition of specialist roles – Nathan Boehlke, MS, RCEP, FAACVPR joined the Eon team as Clinical & Application Specialist and was recently promoted to Manager of Education and Success. Sheri Hahn, MSN, ARNP, FNP-C filled the new role of Director of Clinical and Programmatic Development and is responsible for programmatic development with clients. And Brian Allee, an Epic analytics and
architecture specialist, joined as Director of Systems Integration, rounding out the dev-ops and implementation team.

Ready, Set, Go

AAA Engine Launched and Scaling

In 2019, Eon expanded our proven patient identification and tracking platform to Abdominal Aortic Aneurysms (AAA), something we consider mission critical in our quest to #defydisease. As with most incidental findings, positive AAA’s are not well-surveilled for growth and AAA patients have little to no warning before a rupture. Of those patients who do develop a rupture, only 50% will reach the hospital alive and of those who reach the hospital, 30-50% will not survive surgery. It is Eon’s desire
to stop this cycle so patients can receive the proper intervention before catastrophe strikes.

Eon is committed to expanding AAA and other potentially catastrophic disease identification. We are diligently working to identify more at-risk patients across a multitude of diseases requiring complex care coordination.

Learn More

Future of Healthcare Technology

Together with Mark Cuban

Photo of Eon Team having a disucssion with Mark Cuban

In May, the Eon team sat down with Eon investor and entrepreneur Mark Cuban to discuss the evolution of technology in healthcare. Dr.’s Gerard Silvestri (Medical University of South Carolina), Peter Mazzone (Cleveland Clinic), and George Eapen (MD Anderson) participated in the discussion and shared their perspective on how technology can improve, or sometimes hinder, patient care.

 

The lively dialogue covered a wide range of health tech topics, including AI and deep learning, to healthcare misaligned incentives and what is truly driving increased healthcare costs.

View Recording

Eon Hits The Road

2019 Lung Screening CMS Compliance Tour

Images from Eon's Compliance Tour

At Eon, we pride ourselves on being the experts in lung screening and CMS compliance. Unfortunately, while most lung screening facilities believe their program to be in compliance, they usually are not.

 

Throughout 2019, Eon took initiative and offered free data debt analysis of lung cancer screening submission compliance to healthcare facilities across the United States. These facilities gained a stronger understanding of data deficiencies and were able to course correct.

 

Eon’s own Dr. Aki traveled across the country, meeting with physicians and facilities, to identify pitfalls and optimize workflow and data submission strategies, ensuring programs were 100% compliant.

Fast-Forward To The Future

Unveiling The Eon EPM

2019 was indeed the most exciting year to date for Eon, punctuated by rapid client deployments and the launch of new EonEndu disease engines. We are confident, however, that 2020 will eclipse 2019 with the Eon Electronic Patient Management (EPM) launch.

 

Eon’s advanced Electronic Patient Management (EPM) platform employs specially-engineered software that allows Eon to offer same-day custom software solutions for any desired registry template or customized disease template. This technology condenses months of development into a quick few hours of work, reducing costs while improving efficiencies.

 

Eon EPM also makes it easy to manage multiple patient cohorts. Identification of incidental findings for multiple disease states is automatically captured and made accessible for longitudinal tracking on the EonDirect dashboard. Users are also able to track and submit data to multiple data registries (any of them!), reducing FTE time spent collecting and submitting data.

 

This unrivaled platform is purposefully-built to handle the unique management of each assigned cohort for a patient. Although the information is displayed as a comprehensive patient record, each step of the longitudinal tracking process can be separately performed for each assigned cohort. This makes Eon EPM among the most powerful and customizable solutions available to the market.

EonDirect Lung Community Case Study

Eon continues to impact patient lives and optimize provider workflows across the country. In this case study we look at how a 175 bed community hospital improved their workflow and patient tracking of incidental and lung screening patients using EonDirect.

 

Tracking Patient Cohort:

 

The case study hospital began using EonDirect in January 2018 and began using Eon’s proprietary identification model for pulmonary incidental nodule identification in August as shown in the graph below. Eon’s proprietary identification model had a 90% positive predictive value and resulted in a significant increase in incidentally identified true positive patients.

 

Patient Follow-Up Adherence Rate

 

EonDirect longitudinally tracked all future exams for both patient populations and demonstrated an increased Follow-Up adherence to 98% for both cohorts.  It is important to note that the national adherence rate for recommended clinical follow up for incidental pulmonary nodule patients is just 30%.

 

With and Without EonDirect Comparison

 

The below charts demonstrate the impact EonDirect had on the community hospital’s lung programs. To determine this information, we compared the 35 months prior to implementing EonDirect and the 10 month period following the EonDirect implementation. The chart demonstrates a 3.43 times monthly increase in lung screening exams and a 38.68 times monthly increase in incidental nodule exams.

 


EonDirect Increased Efficiency Between Abnormal Exam to Diagnosis to Treatment

 

The Journal of Oncology Practice published a multi-site study that showed a 36.5-day median time to treatment from the first abnormal radiography result to treatment (http://ascopubs.org/doi/full/10.1200/jop.2015.009605). Using EonDirect, the community hospital was able to demonstrate below average times for the same intervals. By immediately identifying patients at risk and tracking their longitudinal care, EonDirect also increases hospital efficiency by reducing time from Abnormal scan < Diagnosis < Treatment.

 

Reece’s Barrel

A President’s Club Award & A Trip Down Memory Lane

 

“I always wanted a full barrel of Jack Daniel’s whiskey.”

 

This is what I told Christine and Aki the first time I met them. We were sitting in a restaurant in Cincinnati, OH, a few miles away from the Bourbon Trail, getting to know one another.  That might sound like an odd thing to say at a first meeting . And it probably is.

 

Unless you’re from Lincoln County, Tennessee, like me.

 

Lincoln County is about 15 miles down the road from Lynchburg, Tennessee, the famous home of the Jack Daniel’s distillery. Growing up here, whiskey was everything. My grandparents even had a whiskey barrel they used as their TV stand, proudly sitting in the middle of the dining room, plus several more half barrels they used as flower pots. All this, and they were what Southerners would call, “Teetotalers.” They never drank a drop of alcohol. But in Lincoln County, used whiskey barrels in the house are about as common as Ikea credenzas. This is the heart of whiskey country, after all.

 

I remember taking the stopper out of the bung-hole when I was young, smelling inside the barrel and wondering why in the world anyone would want to drink that stuff.  The barrels still had the smell of whiskey inside them, and if the cork was out, it would smell up the whole house.

 

So, when it came time for Christine, Aki and me to decide on a President’s Club sales award at Eon, the decision was easy. We planned a trip to Lynchburg to hand pick a single barrel of Jack Daniel’s. To me, this would be more than a sales award. It was a trip back to childhood.  

 

I remember visiting the Jack Daniel’s distillery when I was 10 years old. It was the first visit that I can remember. My mom took my friend, Paul, and me and we did the tour. There’s a lot to see in the distillery – but what I remember most are the smells. There was the smell of the sour mash bubbling like it was boiling and the smell of warm oak when they opened up the charcoal barrels. Later, when I attended Motlow State College (named after Jack Daniel’s nephew, Lee Motlow), I drove through Lynchburg several times a week, and still remember the smell of sour mash as it filled the air. Those memories all immediately come back any time I catch the faintest scent of Jack Daniel’s whiskey.

 

Resurrecting those memories, and sharing them with my colleagues, was what the trip was really all about. I was sharing a part of my hometown – something that is deeply personal and rooted in my soul and upbringing. The water, the hills, the weather of Lincoln County are all captured in every barrel.

 

Needless to say, when it came time for us to sample different barrels for the selection, we had a lot of discussion about what the proper single barrel for Eon should be. The master taster, “Goose,” told us to look for hints of banana, vanilla, oak, smoke, and pepper, and to pay attention to whether it tasted burnt at the front, middle or back of your tongue. We sampled barrels 19-334, 19-336, and 19-337. Barrel 334 was bright, potent, complex and finished hard while Barrel 337 was smooth, buttery and finished like sweet cream. 336 was average and our first loser. In the end, we chose a barrel that was smart and fiery, a little wild and on edge – and as Goose said, with a “kick-ass finish.” We all agreed, that’s what Eon is all about.

 

 

And so, I am beyond excited to share the contents of this special barrel, Jack Daniels Single Barrel 19-334 with you. Here’s to the old stories it will elicit, and the new stories it will inspire.

 

2018 Year in Review

HAPPY NEW YEAR FROM THE EON TEAM!


The year has flown by and we are extremely excited about what’s in store for 2019. Four years after Dr. Aki said “I’m going to build an app to solve my clinical problem,” EonDirect is the number one lung screening and incidental pulmonary nodule platform, and we are just getting started. We are rapidly implementing in hospital systems across the country and will be installed in over 150 hospitals by summer of 2019.

 

Some of our biggest achievements in 2018 include deploying at HCA’s Continental and Tristar Divisions and rebranding to Eon.

 

HCA Continental and Tristar Divisions Go-Live in 2018

If you remember our 2017 Year in Review Newsletter, we announced the January go-live of EonDirect at HCA’s Continental Division. This November, TriStar Health in Nashville also went live with EonDirect to track and manage incidental nodule and lung screening patients. EonDirect will continue to be rolled out in additional HCA divisions over the next several months.

Rebrand from LungDirect to EonDirect

One question we consistently get from our customers is “What else can you track?” We thought it was an excellent question that needed to be addressed and in order to do so, we knew LungDirect was not a viable market name. In May, LungDirect was rebranded to EonDirect.

Over the past 5 months we have created a revolutionary platform, modular in nature with unlimited capabilities, to allow our customers the ability to track innumerable disease states. EonDirect 4.0 will offer unlimited patient tracking with new identification modules to identify at-risk patients for a multitude of diseases.

 

If you want to be one of the first to identify and track not just lung incidentals, click here to speak with someone from our Eon Team.

 

Get Contacted

 

Lung Cancer Awareness Month

Eon has supported those who serve patients with lung cancer over the past 60 days. During each day of Lung Cancer Awareness Month in November, Eon featured the unsung heroes behind lung cancer by spotlighting a 30 second selfie video of why they do what they do.

 

Eon also promoted the $1,00,000 Software Giveaway and gave away FREE lung screening software with one-click submission to the Lung Cancer Screening Registry. While the giveaway has now ended, Eon is proud to lead the effort in tackling the complexity of lung screening patient management.

 

Watch Videos

 

Creating Impact and Having Fun

At the heart of it all, Eon continues to impact patient lives and optimize provider workflows across the country. If you are interested in learning more about this impact, click here to download our latest case study.

 

Download Case Study

 

Through it all, we have not stopped having FUN!

 

EonDirect as a Lung Cancer Screening Software

I didn’t set out to create a lung cancer screening software platform. I set out to be an Interventional Pulmonologist. When I started med school, I was thinking about impacting patient lives, not starting a company. After fellowship, I was focused on saving the lives of my patients, not creating software. Then in 2014, I diagnosed a patient with stage IV lung cancer who was my same age. This man was not a smoker, lived a very healthy life, and was in fact an avid runner.

 

I was heartbroken and angered that there wasn’t a better system in place to catch lung cancer at an earlier stage. I was determined to change that and announced I would manage 100% of all pulmonary nodules in our patient population. I worked with my hospital to implement process algorithms and quickly realized there was a huge body of work in front of us.

 

A Bold Claim And More Work Than We Expected

 

When I started the lung screening program at my former hospital, I quickly realized how difficult it is to properly implement and run a program. We didn’t have a multidisciplinary lung cancer team so I used my office staff. We were all working together to manage nodule patients and my office staff effectively became nodule coordinators and navigators. Soon we had everyone from compliance to marketing to my clinic staff working to manage our patient population and ensure each patient received appropriate follow-up per evidence-based guidelines.

 

We were using Excel spreadsheets to track patients and the whole process was very manual. It was a ton of work but we “kept it 100” meaning we didn’t miss follow-ups and did our best to identify all incidental patients from our RIS system and EMR. I thought to myself “there’s got to be a better way.” At this point I was solely focused on tracking incidental pulmonary nodules, although lung cancer screening had just been approved for reimbursement by CMS and lung cancer screening software needs started to be on my radar.

 

I began looking into market software solutions to help my clinic manage the nodules we were manually tracking but there wasn’t anything out there built specifically for incidental nodule tracking. In fact, I found out that there were no lung cancer screening software platforms at that time. I did find a few mammogram programs that were trying to mold their software into something that could be used for lung screening but they were grossly inadequate. I talked to other hospitals and clinicians who were facing the same struggles as me and I began to realize that the market needed a better way to identify, organize, and track nodules.

 

The Birth Of A Lung Cancer Screening Software

 

With nothing resembling lung cancer screening software or even an advanced way of tracking nodule patients, I decided to build a solution. I hired a developer and we got to work on creating a solution that automated the entire patient identification and tracking process and I was convinced we were going to solve lung cancer. In 2015, we created our first product and it was dependent on radiologists to use it. It was advanced computer-aided detection software and used deep learning algorithms to assess the malignancy risk of pulmonary nodules based on factors such as nodule size, shape, density, volume, as well as patient demographics such as years smoking, age, gender, and race. We also created a patient tracking program that was populated by the CAD function and allowed clinicians like a Nurse Navigator to better track and manage nodule patients.

 

Matrix Analytics was born (later rebranded to Eon in May of 2018). Our product was groundbreaking, and we were getting amazing feedback from the clinical community, not to mention attracting big-name angel investors. The only problem was we didn’t properly vet the product with radiologists and quickly realized asking them to disrupt their workflow, especially for incidental nodules, was not practical. We were heartbroken but quickly got back to work to develop a product with a good market fit.

 

We quickly created a workaround that still automatically identified patients and registered them to a dashboard but did not require the radiologist to change their workflow and we quickly learned the tracking portion of our software was more valuable than the CAD portion. We went to work on what was then called LungDirect and created another breakthrough in the pulmonology field, a complex patient management software that actually facilitated longitudinal tracking of nodule patients. Because of our previous work with CAD, we were able to apply our proprietary incidental identification deep learning models to our tracking software. The software was also adapted to automate lung screening patient identification and required submission to the Lung Cancer Screening Registry (LCSR).

 

We had created a lung cancer screening software that outperformed anything else on the market and we hadn’t even set out to. We began to further test the software and started to achieve some amazing results with our early adopters. We listened closely to our customers and began to streamline things like data collection from their EMR and RIS systems. We enabled our end users to one-click submit all required data to the LCSR with no manual data entry. This enabled the clinical staff at our customer sites to spend more time with their patients and less time tracking down information and entering data. We focused on 6 main pillars: Software, Identification, Tracking, Automation, Submission, Analytics, and Communication.

 

How We Became Eon

 

We continued to focus on our customers while consistently improving the 6 main pillars of our software. We conquered hospital IT security clearance and became experts in HIPAA and HITECH regulations. Although our earliest intention was to better track incidental nodules we grew our tracking software into a robust lung cancer screening software platform. We soon realized the need for our software wasn’t siloed to lung cancer and pulmonary incidentalomas and many of our clients began asking us to build additional modules to manage other complex disease states. LungDirect no longer described what we were capable of and the perception was we specialized in lung cancer screening software. Our software was built to be moldable and our proprietary deep learning algorithm could be applied to any disease state our customers wanted us to attack. So, we rebranded our company to Eon and renamed our flagship software LungDirect to EonDirect.

 

EonDirect today is so much more than lung cancer screening software. We’re rapidly moving into other disease states at the request of our customers. We are live in 45 facilities and have contracts for 100 more that will be live by summer of 2019. We have grown our team significantly over the past year and are moving to create sea change in the healthcare technology field. We are taking the bottom out of the medical software market and offering such crazy ideas to our customers like free upgrades, no training fees, and unlimited customer support. We want to help facilitate the management of all incidental nodules, catch complex disease at earlier states, and improve the survivability of those patient populations.

 

This is why I get out of bed every morning, this is what keeps me up at night, this is why I founded Eon. I want to personally invite you and your organization to join us in our mission to Defy Disease.

 

Thank you.
-Akrum “Aki” Alzubaidi DO, FCCP